Camosten™ - Clinical Trials
|I Product Info||I Ingredients||I Recommended Use||I Clinical Trials||I Research Brief||I References|
Low USA domestic & international
Indication: bone and teeth strengthening, calcium deficiency, to prevent rickets and osteoporosis, bone fractures, caries, nail fragility, impaired neuromuscular transmission, pregnancy and lactation.
Actions: prevents osteoporosis, strengthens the bone tissues, promotes bone fracture healing, promotes normal growth and development of children, prevents rickets, strengthens the teeth, improves neuromuscular transmission.
Ingredients (per 1 packet – 6.6 g):
Vitamin D (as cholecalciferol) - 80 IU, calcium (as dicalcium phosphate and calcium citrate - 500 mg, magnesium (as magnesium citrate) - 200.0 mg, manganese (as manganese gluconate) - 0.2 mg.
Camosten™ - Clinical Trials:
A randomized, placebo-controlled study documented that calcium citrate supplementation averts bone loss and stabilizes bone density in early postmenopausal women.
Doctor Khashayar Sakhaee and co-authors at the Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas conducted a clinical study to evaluate the effect of calcium supplements on the early stages of osteoporosis.
In the two-year study, 63 healthy, postmenopausal women were separated into two groups - 29 subjects were allocated to the calcium citrate group (were given 400 mg of calcium citrate twice a day) and 34 - to the placebo group. Those in the placebo group took tablets of identical appearance. Bone density was tested at three sites most commonly affected by osteoporosis: the vertebrae in the lower back (spine), the radial shaft (wrist) and the femoral neck (hip). The data indicates:
Calcium citrate supplementation preserved bone mass in the spine, femoral neck, and radial shaft in a group comprised mostly of early postmenopausal women during two years of the trial. The difference in the bone mass between the two groups was significant after two years of calcium citrate treatment.
In another study was evaluated the effect of calcium citrate supplementation on the stone forming propensity in healthy postmenopausal women.
A total of 18 postmenopausal women without stones underwent a randomized trial. During the last 2 days of each phase urine was collected in 24-hour pools for complete stone risk analysis.
Conclusions: Calcium citrate supplementation does not increase the risk of stone formation in healthy postmenopausal women. (26)
An analysis of 15 randomized trials concluded that calcium citrate was absorbed 22% to 27% better than calcium carbonate, whether taken on an empty stomach or with food.
In a randomized crossover study, patients were assigned to an 8-week calcium supplementation period and an 8-week control period. The subjects were given 1 g/day of calcium during the intervention period.
Sixty untreated or treated hypertensive patients (35 men and 25 women, mean age 58 years) with office systolic/diastolic blood pressure >= 140/90 mmHg.
The serum calcium concentration and urinary calcium excretion increased significantly with calcium supplementation. Office, home and 24 h blood pressure were lower in the calcium period than in the control period, although the differences were small (mean +/- SEM office blood pressure: 1.2 +/- 1.2/1.1 +/- 0.7 mmHg; home blood pressure: 1.9 +/- 0.7/1.3 +/- 0.6 mmHg; 24 h blood pressure: 1.2 +/- 0.8/0.9 +/- 0.5 mmHg,), and significant only for home systolic and diastolic blood pressures. (11)
A randomized, double-blinded, placebo-controlled trial was performed with 36 282 postmenopausal women, aged 50 to 79 years, who were already enrolled in the dietary modification and/or hormone therapy arms of the Women's Health Initiative clinical trial. Women were randomized at their first or second annual visit to receive a dose of 1000 mg of elemental calcium plus 400 IU of cholecalciferol (vitamin D) or placebo daily. Change in body weight was ascertained annually for an average of 7 years.
Calcium plus cholecalciferol supplementation has a small effect on the prevention of weight gain, which was observed primarily in women who reported inadequate calcium intakes. (16)
Numerous observational studies have found supplemental calcium and vitamin D to be associated with reduced risk of common cancers.
The purpose of this analysis was to determine the efficacy of calcium alone and calcium plus vitamin D in reducing incident cancer risk of all types.
This was a 4-y, population-based, double-blind, randomized placebo-controlled trial. The primary outcome was fracture incidence, and the principal secondary outcome was cancer incidence. The subjects were 1179 community-dwelling women randomly selected from the population of healthy postmenopausal women aged >55 y in a 9-county rural area of Nebraska. Subjects were randomly assigned to receive 1400–1500 mg supplemental calcium/d alone (Ca-only), supplemental calcium plus 1100 IU vitamin D3/d (Ca + D), or placebo.
When analyzed by intention to treat, cancer incidence was lower in the Ca + D women than in the placebo control subjects (P < 0.03). With the use of logistic regression, the unadjusted relative risks (RR) of incident cancer in the Ca + D and Ca-only groups were 0.402 (P = 0.01) and 0.532 (P = 0.06), respectively. When analysis was confined to cancers diagnosed after the first 12 mo, RR for the Ca + D group fell to 0.232 (CI: 0.09, 0.60; P < 0.005) but did not change significantly for the Ca-only group.
Improving calcium and vitamin D nutritional status substantially reduces all-cancer risk in postmenopausal women. (27)
In 1999 Howard J. Heller, MD and his colleagues compared the calcium absorption of calcium citrate and calcium carbonate supplementations after a single oral dose (500 mg calcium), taken with a meal.
This study was conducted to compare pharmacokinetic indices of calcium absorption after a single oral (500 mg calcium) load of calcium citrate and calcium carbonate.
In conclusion, calcium citrate was shown to be much more bioavailable than calcium carbonate. (28)